April 24, 2018 / 8:46 PM / 5 months ago

BRIEF-Mirati Therapeutics Announces Progress Of Lead Programs

April 24 (Reuters) - Mirati Therapeutics Inc:

* MIRATI THERAPEUTICS ANNOUNCES PROGRESS OF LEAD PROGRAMS AND PROVIDES UPDATED POSITIVE CLINICAL TRIAL RESULTS FOR IMMUNO-ONCOLOGY COMBINATION TRIALS

* MIRATI THERAPEUTICS INC - MRTX849 ON TRACK FOR AN INVESTIGATIONAL NEW DRUG SUBMISSION IN Q4 OF 2018

* MIRATI THERAPEUTICS - SITRAVATINIB BEING EVALUATED IN PHASE 2 STUDY IN COMBINATION WITH NIVOLUMAB HAS BEEN WELL-TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below